31 May
  • By Alicia Clough
  • Cause in

CD Access to Provide Special Access Program for Duchenne Muscular Dystrophy Patients in Canada

NEWPORT BEACH, Calif., May 31, 2017 –  CD Access is a new nonprofit that provides patients access to drugs and therapies that are currently unavailable through clinical trial or prescription. CD Access’ first program allows Duchenne muscular dystrophy patients in Canada that previously participated in a clinical trial for drisapersen to begin redosing through a […]

READ MORE
15 May
  • By Alicia Clough
  • Cause in

CureDuchenne Support Duchenne Muscular Dystrophy Patients in Nepal

CureDuchenne firmly believes in working together to help any child with Duchenne muscular dystrophy find the support they need. Duchenne is a disorder which knows no cultural, economic, or social boundaries.  This fatal genetic muscle disease affects more than 300,000 children worldwide. Especially affected are muscular dystrophy patients in Nepal, as the region lacks resources […]

READ MORE
04 May
  • By Alicia Clough
  • Cause in

Eighth Annual Champions to CureDuchenne Gala Raises More Than $378,000 Towards Finding a Cure for Duchenne Muscular Dystrophy

Austin, Texas, May 4, 2017 – On April 8, hundreds gathered at The University of Texas Golf Club for a common goal, raising awareness and funds to help CureDuchenne in its mission to find a cure for Duchenne muscular dystrophy, a fatal genetic disease. The eighth annual Champions to CureDuchenne, emceed by Jim Spencer, chief […]

READ MORE
01 May
  • By Alicia Clough
  • Cause in

Anaheim Ducks Captain Ryan Getzlaf Supports CureDuchenne In 7th Annual Getzlaf Golf Shootout to Help Save Lives of Those with Duchenne

Newport Beach, Calif., May 1, 2017 –  Hitting a hole in one will feel twice as nice at the 7th Annual Getzlaf Golf Shootout, hosted by Anaheim Ducks Captain Ryan Getzlaf, because all funds raised will benefit CureDuchenne and their mission to find a cure for Duchenne muscular dystrophy. This year’s event will be held […]

READ MORE
27 Mar
  • By Alicia Clough
  • Cause in

Leader in Cure, Care and Community for Duchenne Muscular Dystrophy CureDuchenne Launches New Website

NEWPORT BEACH, Calif., March 27, 2017 – CureDuchenne, the leading nonprofit focused on finding a cure for Duchenne muscular dystrophy, launched a new website today at www.CureDuchenne.org to further reflect its mission which focuses on improving and extending the lives of all those with Duchenne. Duchenne muscular dystrophy is a fatal genetic disorder that causes […]

READ MORE
21 Mar
  • By Alicia Clough
  • Cause in

Eighth Annual Champions to CureDuchenne Gala Presented by Fired Up Charity Foundation To Be Held April 8 at The University of Texas Golf Club

(Austin, Texas) March 21, 2017 – Some champions are made on a field and some become champions by giving from the heart. On April 8, hundreds of champions committed to finding a cure for Duchenne muscular dystrophy will gather at The University of Texas Golf Club for the eighth annual Champions to CureDuchenne gala to […]

READ MORE
14 Mar
  • By Alicia Clough
  • Cause in

Napa In Newport Raises $1 Million To Help Find a Cure for Duchenne Muscular Dystrophy

NEWPORT BEACH, Calif., March 14, 2017 – More than 400 people gathered at the Ritz-Carlton on Saturday, March 4 to enjoy the nectar of top Napa Valley wineries and help find a cure for Duchenne muscular dystrophy. The third annual Napa in Newport wine auction, powered by Karma, raised $1 million to support CureDuchenne’s mission […]

READ MORE
27 Feb
  • By leilanifera
  • Cause in

CureDuchenne Ventures Invests in New Gene Editing Company Exonics Therapeutics to Advance CRISPR/Cas9 Therapy for Duchenne Muscular Dystrophy

NEWPORT BEACH, Calif., February 27, 2017 – CureDuchenne Ventures, a subsidiary of the nonprofit CureDuchenne that funds research to find a cure for Duchenne muscular dystrophy, announced today that they have committed $5 million in seed financing in Exonics Therapeutics, a new biotechnology company focused on utilizing gene editing technologies like CRISPR/Cas9 to advance the […]

READ MORE